Organization
University of Padua School of Medicine
10 abstracts
Abstract
Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial.Org: Department of Experimental Oncology, Milano, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Vall d'Hebron University Hospital, Bergonié Institute,
Abstract
Association of tumor-infiltrating lymphocytes (TILs) and immune signatures with PAM50 intrinsic subtyping hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of two multicentric neoadjuvant trials.Org: University of Padua School of Medicine, University of Padova, Veneto Institute of Oncology IOV-IRCCS, Reveal Genomics Srl, Istituto Oncologico Veneto IRCCS,
Abstract
A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.Org: Department of Surgery Oncology and Gastroenterology, University of Padua, Padova, MO, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV, Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy, Azienda Unità Sanitaria Locale-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Reggio Emilia, Italy, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom,
Abstract
Prognosis and tumor-infiltrating lymphocytes (TILs) in estrogen receptor (ER)-low metastatic breast cancer (MBC): Analysis from a large multi-institutional cohort and the TONIC phase II trial with nivolumab.Org: University of Padova, Istituto Oncologico Veneto IRCCS, Fondazione IRCCS INT, Milan, Italy, Netherlands Cancer Institute, University Hospital of Modena,
Abstract
Understanding resistance in V600E BRAF advanced colon cancer treated with BRAF inhibitors plus anti-EGFR antibodies +/- MEK inhibitors: The URBAN study.Org: Medical Oncology 1, Venetian Institute of Oncology-IRCCS, Padua, Padua, Italy, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy, Department of Medicine (DIMED) University of Padua and Veneto Institute of Oncology (IOV-IRCCS ),
Abstract
Gene expression profiling of paired primary breast cancers and brain metastases to identify brain metastases-specific biological changes.Org: University of Padua School of Medicine, Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Montefiore Medical Center, Albert Einstein College of Medicine, UOSD Hereditary Tumors, Veneto Institute of Oncology IOV-IRCCS, CHU Montpellier,
Abstract
Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial.Org: University of Padua School of Medicine, Veneto Institute of Oncology IOV-IRCCS Padua, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Department of Oncology, Hematology, and Respiratory Diseases, Modena University,
Abstract
APHAERETIC PROCEDURES AND INTRAVENOUS IMMUNOGLOBULINS IN ADDITION TO CONVENTIONAL THERAPY TO TREAT PREGNANT WOMEN WITH HIGH-RISK ANTIPHOSPHOLIPID ANTIBODY SYNDROME. A PROSPECTIVE COHORT STUDY Org: University of Padua School of Medicine, University Hospital, Padua, Italy,
Abstract
A phase iii randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on standard of care in patients with active class iii or iv lupus nephritisOrg: Northwell Health, New Hyde Park, NY, University of North Carolina at Chapel Hill, University of California San Francisco, Keio University School of Medicine, Hospital Fernández,
Abstract
ARE WE DOING ENOUGH FOR CHILDREN WITH KAWASAKI DISEASE IN 2002 ?Org: University of Florence, AOUC, University of Padua School of Medicine, G.Gaslini-Children Hospital, ICP Milan,